Analyst firms · Barclays · CYTK
Barclays CYTK price target and rating history
Cytokinetics Incorporated (CYTK) · Health Care
Barclays rates Cytokinetics Incorporated (CYTK) Overweight with a $87 price target, as of its latest action on Jan 28, 2026. It has published 3 rating actions on CYTK since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. Barclays's $87 is 8% below that.
- Current rating
- Overweight
- Price target
- $87
- Median target, all firms
- $95
- Actions on CYTK
- 3
Barclays price target on CYTK
Every Barclays rating on CYTK
- Jan 28, 2026
- Apr 24, 2025
- Jul 20, 2021
How other firms rate CYTK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $115 | Jun 29, 2026 |
| Citigroup | Buy | $99 | May 19, 2026 |
| Wells Fargo | Overweight | $95 | Apr 10, 2026 |
| Barclays | Overweight | $87 | Jan 28, 2026 |
| Goldman Sachs | Buy | $95 | Dec 18, 2025 |
Questions about Barclays and CYTK
- What is Barclays's price target for CYTK?
- Barclays's latest stated price target for Cytokinetics Incorporated (CYTK) is $87, from its action on Jan 28, 2026.
- What is Barclays's rating on CYTK?
- Barclays rates CYTK Overweight, a bullish rating, as of Jan 28, 2026.
- When did Barclays last change its view on CYTK?
- On Jan 28, 2026, Barclays resumes coverage at Overweight, price target $87.
- How does Barclays's CYTK target compare with other analysts?
- Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. Barclays's $87 is 8% below that.
More CYTK rating histories
All Barclays ratingsCYTK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.